Manatt Financial Services Partner Troy Zander and Associate Francis Mascarenhas represented Oxford Finance LLC in the closing of a landmark $500 million debt financing agreement with Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics is an existing borrower of Oxford and in their expanded partnership, $75 million is funded at close, with up to $425 million of additional availability.
Vera is advancing atacicept for the treatment of Berger’s disease, and in connection with this debt facility, announced positive topline Phase 3 data that continues to support its potential as a disease-modifying therapy.
Learn more about the deal here.